drugset
drugset / Trial / NCT01511497

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study Of PF-04427429 In Healthy Women Volunteers

NCT01511497 ↗

Phase 1 Completed 31 enrolled Pfizer
RandomizedSingle-groupQuadruple-blindTreatment

Summary

The purpose of this study is to determine the safety, tolerability, pharmacokinetics, and pharmacodynamics of PF-04427429 in healthy women.

Timeline

Start
2011-10
Primary completion
2013-01
Completion
2013-01

Drugs

EvaluationDrugModalityDoseRoute
Subject PF-04427429 Unknown 300 mg Intravenous
Subject PF-04427429 Unknown 1000 mg Intravenous
Subject PF-04427429 Unknown 1500 mg Intravenous
Subject PF-04427429 Unknown 2000 mg Intravenous

Indications

migraine disorder